← Back to Screener
Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)
Price$8.90
Favorite Metrics
Price vs S&P 500 (26W)-62.05%
Price vs S&P 500 (4W)23.99%
Market Capitalization$251.54M
All Metrics
Book Value / Share (Quarterly)$7.53
P/TBV (Annual)2.36x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-26.43%
Cash Flow / Share (Quarterly)$-2.62
Price vs S&P 500 (YTD)40.23%
Net Profit Margin (TTM)-80.19%
EPS (TTM)$-2.39
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-2.39
Revenue Growth (5Y)53.90%
EPS (Annual)$-2.40
ROI (Annual)-30.74%
Net Profit Margin (5Y Avg)-357.81%
Cash / Share (Quarterly)$8.13
Revenue Growth QoQ (YoY)-68.39%
ROA (Last FY)-24.26%
Revenue Growth TTM (YoY)-46.14%
EBITD / Share (TTM)$-2.67
ROE (5Y Avg)-32.16%
Operating Margin (TTM)-92.97%
Cash Flow / Share (Annual)$-2.62
P/B Ratio1.18x
P/B Ratio (Quarterly)0.81x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)0.25x
Net Interest Coverage (TTM)8.07x
ROA (TTM)-22.03%
EV / EBITDA (TTM)0.21x
EPS Incl Extra (Annual)$-2.40
Current Ratio (Annual)6.64x
Quick Ratio (Quarterly)6.50x
3-Month Avg Trading Volume0.52M
52-Week Price Return-14.08%
EV / Free Cash Flow (Annual)97.69x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$10.48
P/S Ratio (Annual)3.07x
Asset Turnover (Annual)0.30x
52-Week High$24.17
Operating Margin (5Y Avg)-362.44%
EPS Excl Extra (Annual)$-2.40
CapEx CAGR (5Y)-33.28%
Tangible BV CAGR (5Y)51.57%
26-Week Price Return-53.30%
Quick Ratio (Annual)6.50x
13-Week Price Return14.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.64x
Enterprise Value$20.635
Revenue / Share Growth (5Y)44.96%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)-13.03%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-80.19%
Cash / Share (Annual)$8.13
3-Month Return Std Dev54.11%
Net Income / Employee (TTM)$-1
ROE (Last FY)-30.74%
Net Interest Coverage (Annual)19.72x
EPS Basic Excl Extra (Annual)$-2.40
P/FCF (TTM)1.22x
Receivables Turnover (TTM)17.20x
EV / Free Cash Flow (TTM)3.61x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.39
Receivables Turnover (Annual)17.20x
ROI (TTM)-28.65%
P/S Ratio (TTM)3.07x
Pretax Margin (5Y Avg)-357.47%
Revenue / Share (Annual)$3.00
Tangible BV / Share (Annual)$10.18
Price vs S&P 500 (52W)-49.17%
Year-to-Date Return44.37%
5-Day Price Return4.61%
EPS Normalized (Annual)$-2.40
ROA (5Y Avg)-20.90%
Net Profit Margin (Annual)-80.19%
Month-to-Date Return14.64%
Cash Flow / Share (TTM)$3.73
EBITD / Share (Annual)$-2.67
Operating Margin (Annual)-92.96%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-28.42%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-2.39
P/TBV (Quarterly)2.28x
P/B Ratio (Annual)0.81x
Pretax Margin (TTM)-80.19%
Book Value / Share (Annual)$7.53
Price vs S&P 500 (13W)11.62%
Beta2.48x
P/FCF (Annual)10.37x
Revenue / Share (TTM)$2.92
ROE (TTM)-29.13%
52-Week Low$5.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.06
4.06
4.06
4.05
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARCTArcturus Therapeutics Holdings Inc. Common Stock | 3.07x | -46.14% | — | — | $8.90 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Arcturus Therapeutics develops mRNA medicines focused on infectious disease vaccines and rare liver and respiratory disease therapies. Its pipeline includes vaccine candidates for influenza and COVID-19 variants, as well as programs for rare genetic conditions. The company aims to address significant unmet medical needs in high-value therapeutic areas.